Immutep Discontinues Phase III NSCLC Trial Due to Futility Analysis
Summary
Immutep has halted its Phase III TACTI-004 study for eftilagimod alfa in NSCLC due to futility, a major clinical setback, though it will extend the company's cash runway.
Key Events
-
Phase III Trial Discontinued
The TACTI-004 Phase III study evaluating eftilagimod alfa in first-line non-small cell lung cancer (NSCLC) has been discontinued.
-
Futility Analysis Outcome
An Independent Data Monitoring Committee (IDMC) recommended discontinuation following a planned interim futility analysis, indicating the trial did not meet efficacy endpoints.
-
Extended Cash Runway
The company anticipates its cash runway will be extended well beyond Q2 CY2027 due to the cessation of trial expenses, providing financial flexibility despite the clinical setback.
Analysis
Immutep Limited announced the discontinuation of its TACTI-004 Phase III study for eftilagimod alfa in first-line non-small cell lung cancer (NSCLC) following an interim futility analysis. This represents a significant clinical setback for the company's lead candidate, as the trial did not meet its efficacy endpoints. While the discontinuation will extend the company's cash runway beyond Q2 CY2027 by reducing trial expenses, the primary impact is the failure of a late-stage asset, which could lead to a re-evaluation of the company's pipeline and future development strategy. Investors should monitor the comprehensive review of the data and the company's updated capital allocation priorities.
At the time of this filing, IMMP was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.3M. The 52-week trading range was $0.46 to $3.53. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.